{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:49Z","timestamp":1790916829993,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":214,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101358","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:50:23Z","timestamp":1786416623000},"page":"101358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neoantigen cancer vaccines in the mRNA Era: antigen selection, platform engineering, and clinical translation"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6774-0110","authenticated-orcid":false,"given":"Minglu","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.ctarc.2026.101358_bib0001","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"issue":"6230","key":"10.1016\/j.ctarc.2026.101358_bib0002","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101358_bib0003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"25","key":"10.1016\/j.ctarc.2026.101358_bib0004","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101358_bib0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-019-0787-5","article-title":"Tumor neoantigens: from basic research to clinical applications","volume":"12","author":"Jiang","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101358_bib0006","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ctarc.2026.101358_bib0007","first-page":"126","article-title":"Targeting cancer-specific mutations by T cell receptor gene therapy","volume":"34","author":"Blankenstein","year":"2015","journal-title":"Curr. Opin. Immunol."},{"issue":"7662","key":"10.1016\/j.ctarc.2026.101358_bib0008","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"7662","key":"10.1016\/j.ctarc.2026.101358_bib0009","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"issue":"7738","key":"10.1016\/j.ctarc.2026.101358_bib0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"issue":"7738","key":"10.1016\/j.ctarc.2026.101358_bib0011","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101358_bib0012","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7607","key":"10.1016\/j.ctarc.2026.101358_bib0013","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"issue":"7549","key":"10.1016\/j.ctarc.2026.101358_bib0014","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"issue":"470","key":"10.1016\/j.ctarc.2026.101358_bib0015","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5516","article-title":"Noncoding regions are the main source of targetable tumor-specific antigens","volume":"10","author":"Laumont","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"7528","key":"10.1016\/j.ctarc.2026.101358_bib0054","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"6184","key":"10.1016\/j.ctarc.2026.101358_bib0016","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101358_bib0017","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat. Med."},{"issue":"6280","key":"10.1016\/j.ctarc.2026.101358_bib0018","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"7681","key":"10.1016\/j.ctarc.2026.101358_bib0019","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"Luksza","year":"2017","journal-title":"Nature"},{"issue":"7749","key":"10.1016\/j.ctarc.2026.101358_bib0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"issue":"7681","key":"10.1016\/j.ctarc.2026.101358_bib0021","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101358_bib0022","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-cancerbio-061521-082114","article-title":"Targeting driver oncogenes and other public neoantigens using T cell receptor-based cellular therapy","volume":"7","author":"Martinov","year":"2023","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.ctarc.2026.101358_bib0023","doi-asserted-by":"crossref","unstructured":"Hao, Q., Long, Y., Yang, Y., Chen, J., Huang, J. Development and clinical applications of therapeutic cancer vaccines with individualized and shared neoantigens. Vaccines. 2024;12(7):722. doi:10.3390\/vaccines12070722.","DOI":"10.3390\/vaccines12070717"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101358_bib0024","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13073-019-0666-2","article-title":"Best practices for bioinformatic characterization of neoantigens for clinical utility","volume":"11","author":"Richters","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.ctarc.2026.101358_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.836821","article-title":"Cancer neoantigens: challenges and future directions for prediction, prioritization, and validation","volume":"12","author":"Borden","year":"2022","journal-title":"Front. Oncol."},{"issue":"W1","key":"10.1016\/j.ctarc.2026.101358_bib0026","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucl. Acid. Res."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101358_bib0027","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101358_bib0028","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nbt.4313","article-title":"Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification","volume":"37","author":"Bulik-Sullivan","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ctarc.2026.101358_bib0029","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3389\/fimmu.2018.01716","article-title":"Predicting antigen presentation: from peptides to T cell recognition","volume":"9","author":"Gfeller","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101358_bib0030","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"issue":"7528","key":"10.1016\/j.ctarc.2026.101358_bib0031","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101358_bib0032","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101358_bib0033","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","article-title":"Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction","volume":"46","author":"Abelin","year":"2017","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101358_bib0034","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41587-019-0322-9","article-title":"A large peptidome dataset improves HLA class I epitope prediction across most of the human population","volume":"38","author":"Sarkizova","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101358_bib0035","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.cell.2017.09.050","article-title":"MHC-I genotype restricts the oncogenic mutational landscape","volume":"171","author":"Marty","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101358_bib0036","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cell.2017.11.043","article-title":"Antigen identification for orphan T cell receptors expressed on tumor-infiltrating lymphocytes","volume":"172","author":"Gee","year":"2018","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.ctarc.2026.101358_bib0037","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"6236","key":"10.1016\/j.ctarc.2026.101358_bib0038","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2026.101358_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101358_bib0040","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"7963","key":"10.1016\/j.ctarc.2026.101358_bib0041","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101358_bib0042","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101358_bib0043","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101358_bib0044","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","article-title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation","volume":"37","author":"Miao","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"8056","key":"10.1016\/j.ctarc.2026.101358_bib0045","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"issue":"8054","key":"10.1016\/j.ctarc.2026.101358_bib0046","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"issue":"10427","key":"10.1016\/j.ctarc.2026.101358_bib0047","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"7559","key":"10.1016\/j.ctarc.2026.101358_bib0048","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"1\u20132","key":"10.1016\/j.ctarc.2026.101358_bib0049","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101358_bib0051","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101358_bib0052","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101358_bib0053","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:58:37Z","timestamp":1790913517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":53,"alternative-id":["S2468294226002698"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101358","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoantigen cancer vaccines in the mRNA Era: antigen selection, platform engineering, and clinical translation","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101358"}}